Clinical trial
Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute…
NCT00279773 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00279773 |
|---|---|
| Title | Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia |
| Official title | A Phase I Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | TKI258 |
| Enrollment | 34 |
| Start date | Sep 1, 2004 |
| Primary completion | Oct 1, 2007 |
| First posted | Jan 20, 2006 |
| Last update posted | Jun 30, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: